NuCana (NCNA) Projected to Post Quarterly Earnings on Thursday

NuCana (NASDAQ:NCNA) is expected to be issuing its results before the market opens on Thursday, August 13th. Analysts expect NuCana to announce earnings of ($2.6514) per share for the quarter.

NuCana (NASDAQ:NCNA) last announced its earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.64) by $1.39.

NuCana Price Performance

Shares of NuCana stock opened at $1.44 on Wednesday. The stock has a market capitalization of $5.99 million, a price-to-earnings ratio of -0.48 and a beta of 2.25. NuCana has a twelve month low of $1.21 and a twelve month high of $7.22. The company has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.90.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, NuCana has an average rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.